Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging
- PMID: 22782510
- PMCID: PMC3569033
- DOI: 10.1001/archneurol.2011.3029
Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging
Abstract
Objective: To determine whether magnetic resonance imaging measurements observed in the Alzheimer Disease Neuroimaging Initiative (ADNI) convenience sample differ from those observed in the Mayo Clinic Study of Aging (MCSA) population-based sample.
Design: Comparison of 2 samples.
Setting: Fifty-nine recruiting sites for the ADNI in the United States and Canada and the MCSA, a population-based cohort in Olmsted County, Minnesota.
Patients: Cognitively normal subjects and amnestic subjects with mild cognitive impairment were selected from the ADNI convenience cohort and MCSA population-based cohort. A simple random sample of subjects from both cohorts in the same age range was selected, and a second sample applied matching for age, sex, educational level, apolipoprotein E genotype, and Mini-Mental State Examination score.
Main outcome measures: Baseline hippocampal volumes and annual percentage of decline in hippocampal volume.
Results: In the population-based sample, MCSA subjects were older, had less education, performed worse on the Mini-Mental State Examination, and had a family history of Alzheimer disease less often than did ADNI subjects. Baseline hippocampal volumes were larger in ADNI compared with MCSA cognitively normal subjects in the random sample, although no differences were observed after matching. Rates of decline in hippocampal volume were greater in the ADNI compared with the MCSA for cognitively normal subjects and those with amnestic mild cognitive impairment, even after matching.
Conclusions: Rates of decline in hippocampal volume suggest that ADNI subjects have a more aggressive brain pathologic process than MCSA subjects and hence may not be representative of the general population. These findings have implications for treatment trials that use ADNI-like recruitment mechanisms and for studies validating new diagnostic criteria for Alzheimer disease in its various stages.
Figures



References
-
- Chetelat G, Desgranges B, De La Sayette V, et al. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport. 2002;13:1939–1943. - PubMed
-
- Ferreira LK, Diniz BS, Forlenza OV, et al. Neurostructural predictors of Alzheimer's disease: A meta-analysis of VBM studies. Neurobiology of aging. 2009 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 AG030514/AG/NIA NIH HHS/United States
- R01-AG023195/AG/NIA NIH HHS/United States
- R01 AG034676/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- U24-AG026395/AG/NIA NIH HHS/United States
- R01 AG023195/AG/NIA NIH HHS/United States
- R01-AG11378/AG/NIA NIH HHS/United States
- P50-AG16574/AG/NIA NIH HHS/United States
- R01-HL70825/HL/NHLBI NIH HHS/United States
- U24 AG026395/AG/NIA NIH HHS/United States
- R01 DC010367/DC/NIDCD NIH HHS/United States
- R01 AG037491/AG/NIA NIH HHS/United States
- U01 AG006786/AG/NIA NIH HHS/United States
- R21-AG38736/AG/NIA NIH HHS/United States
- R01-DC010367/DC/NIDCD NIH HHS/United States
- U01-AG024904/AG/NIA NIH HHS/United States
- R01-AG037491/AG/NIA NIH HHS/United States
- 90BC0009/BC/NCI NIH HHS/United States
- R01-AG034676/AG/NIA NIH HHS/United States
- K01-AG028573/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- U19 AG010483/AG/NIA NIH HHS/United States
- U01-AG024904-01/AG/NIA NIH HHS/United States
- R01 AG015866/AG/NIA NIH HHS/United States
- R01 AG011378/AG/NIA NIH HHS/United States
- R01 HL070825/HL/NHLBI NIH HHS/United States
- K01 AG028573/AG/NIA NIH HHS/United States
- R01-AG15866/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- R21 AG038736/AG/NIA NIH HHS/United States
- U01-AG06786/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical